Trial · NCT07428512
Comparison of the Effectiveness of 5% and 10% Dextrose Treatments in Patients With Chronic Shoulder Pain: Ultrasound-Guided Perineural Injection
NCT07428512, Not applicable, Completed, Ankara City Hospital Bilkent
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of the Effectiveness of 5% and 10% Dextrose Treatments in Patients With Chronic Shoulder Pain: Ultrasound-Guided Perineural Injection. Trials, record NCT07428512. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07428512
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of the Effectiveness of 5% and 10% Dextrose Treatments in Patients With Chronic Shoulder Pain: Ultrasound-Guided Perineural Injection
- NCT number
- NCT07428512
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 120 participants, actual
- Lead sponsor
- Ankara City Hospital Bilkent
- Conditions
- Chronic Shoulder Pain
- Interventions
- dextrose
- First posted
- 2026-02-23
- Last updated
- 2026-02-23
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analog Scale | baseline,after 1 month and 3 months changes | Patients indicate their pain on a 100 mm line, where 0 represents "no pain" and 100 represents "unbearable pain." The distance from 0 to the patient's mark reflects pain severity. |
| Primary | Shoulder Range of Motion (ROM) | baseline,after 1 month and 3 months changes | Clinician-assessed using a standard goniometer. Passive flexion, abduction, internal rotation, and external rotation of the affected shoulder will be measured. |
| Primary | Shoulder Pain and Disability Index (SPADI) | baseline,after 1 month and 3 months changes | Includes two subscales: pain (5 items) and disability (8 items). Responses are scored from 0-10. Subscale scores are calculated as a percentage of the maximum possible score, with higher scores indicating increased pain and reduced shoulder function. |
| Primary | Kinesiophobia | baseline,after 1 month and 3 months changes | Assessed using the Tampa Scale of Kinesiophobia (17 items, 4-point Likert scale, total score 17-68). Higher scores indicate higher fear of movement. |
| Secondary | Short Form-12 (SF-12) questionnaire | baseline,after 1 month and 3 months changes | Assessed using the Short Form-12 (SF-12) questionnaire. The SF-12 evaluates physical and mental health dimensions, including physical functioning, social functioning, role limitations due to physical and emotional problems, mental health, energy/fatigue, pain, and general health perception. |
| Secondary | Supraspinatus Muscle and Tendon Thickness | baseline,after 1 month and 3 months changes | Measured by ultrasound (LOGIQ 9 device). Supraspinatus tendon thickness: Measured in the Crass position, with the shoulder in extension, adduction, and external rotation. Measurement is taken 10 mm lateral to the intra-articular portion of the long head of the biceps tendon at the rotator interval. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07428512
GET https://conductscience.org/api/trials/v1/NCT07428512/registered